GPT and neutropenia: In terms of safety, grade ≥ 3 treatment-related adverse events occurred in 34% of patients (mainly neutropenia and AST/ALT increase), while grade ≥ 3 immune-mediated adverse events occurred in 8% of patients (mainly ALT increase and rash).